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OBJECTIVE: To evaluate whether postpartum nonsteroi-
dal antiinflammatory drug (NSAID) administration is
associated with increased blood pressure in women with
hypertensive disorders of pregnancy and to estimate the
association between NSAID administration and use of
opioid medication.
METHODS: We conducted a retrospective cohort study
of women with hypertensive disorders of pregnancy.
Patients were analyzed in two groups according to
whether they received NSAIDs postpartum. Study par-
ticipants were women delivered at a tertiary care center
from 2008 to 2015. The primary outcome was change in
mean arterial pressure during the postpartum period.
Secondary outcomes were postpartum pain scores,
cumulative postpartum opioid requirement, initiation
or dose escalation of antihypertensive agents, and
adverse postpartum outcomes including acute renal
failure, change in hematocrit, and maternal readmission
for hypertensive disorder.
RESULTS: Two hundred seventy-six women with hyper-
tensive disorders of pregnancy were included (129
NSAID-unexposed and 147 NSAID-exposed). Postpar-
tum NSAID administration was not associated with
a statistically significant change in mean arterial pressure
compared with no NSAID administration (20.7 vs 21.8;
mean difference 1.10, 95% CI21.44 to 3.64). Similarly, no
difference was observed between the cohorts in terms of
need for initiation or escalation in dose of antihyperten-
sive agents or maternal readmission for hypertensive dis-
order. The study was underpowered to determine
whether NSAID administration was associated with any
difference in less frequent secondary outcomes (eg, inci-
dence of acute renal insufficiency, need for postpartum
transfusion) or cumulative opioid use.
CONCLUSION: Nonsteroidal antiinflammatory drug
administration to postpartum patients with hypertensive
disorders of pregnancy is not associated with a change in
blood pressure or requirement for antihypertensive
medication.
(Obstet Gynecol 2018;132:1471–6)
DOI: 10.1097/AOG.0000000000002979
Hypertensive disorders of pregnancy (gestationalhypertension; preeclampsia; eclampsia; hemoly-
sis, elevated liver enzymes, low platelet count syn-
drome; chronic hypertension; and superimposed
preeclampsia) complicate 10% of pregnancies.1 In
2013, the American College of Obstetricians and Gy-
necologists’ Task Force on Hypertension in Pregnancy
issued a recommendation against use of nonsteroidal
antiinflammatory drugs (NSAIDs) in women with
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hypertensive disorders of pregnancy that persist greater
than 24 hours after delivery, suggesting these agents
contribute to increased blood pressure (BP).2 In non-
obstetric populations, NSAIDs are well known to con-
tribute to a small but significant increase in BP, which
seems to be more pronounced in those on antihyper-
tensive therapy. The mechanism of action is likely
through NSAID inhibition of renal prostaglandins,
leading to increased intravascular volume.3,4
Ascertaining the safety of NSAIDs during the
postpartum period for women with hypertensive
disorders of pregnancy is of clinical importance,
because NSAIDs are a mainstay of analgesia for
postpartum and postcesarean patients. Avoidance of
NSAIDs typically results in use of alternative medi-
cation such as acetaminophen, opioid pain medica-
tions, or other pain adjuncts (eg, gabapentin, lidocaine
patch). Increasing the use of opioid pain medication is
particularly problematic in light of the present opioid
use disorder epidemic. Evaluating the safety of
NSAID administration for postpartum women with
hypertensive disorders is therefore important.
We aimed to evaluate whether the administration of
NSAIDs postpartum to women with hypertensive dis-
orders of pregnancy was associated with worsening of
hypertension postpartum. Secondarily, we also aimed to
evaluate the association between receipt of postpartum
NSAIDs and consumption of opioid pain medication.
MATERIALS AND METHODS
This was a retrospective cohort study of women with
hypertensive disorders of pregnancy delivered at
Thomas Jefferson University Hospital between Janu-
ary 2008 and May 2015. This study was approved by
the institutional review board at Thomas Jefferson
University. Patients with hypertensive disorders of
pregnancy were identified from the electronic medical
record using International Classification of Diseases,
9th Revision codes (Box 1). Patient charts were re-
viewed to determine the patient’s hypertensive disor-
der according to the 2013 Hypertension Task Force
definitions.
Maternal demographic information as well as
clinical data were abstracted by two authors (S.M.
and A.B.). Training on data abstraction was provided
by maternal–fetal medicine physicians (H.B.A. and A.
R.), and data abstraction was initially overseen until
accurate independent abstraction was achieved. Data
abstraction questions or inconsistencies were resolved
by a physician on review of the medical record. Data
were stored in a secure REDCap database. Demo-
graphic data collected included maternal age, race,
parity, and gestational age at delivery. Maternal
medical characteristics (mode of delivery, medical
comorbidities such as hypertension, diabetes, auto-
immune disease, preexisting renal disease, tobacco
use) were recorded. Preexisting renal disease was
defined if either a previous renal diagnosis had been
established by a nephrologist or the patient had pro-
teinuria (greater than 300 mg per 24-hour urine pro-
tein or urine protein:creatinine ratio greater than 0.3)
or elevation in creatinine 1.0 mg/dL or greater before
20 weeks of gestation. The patient’s hypertensive diag-
nosis, according to the American College of Obstetri-
cians and Gynecologists’ 2013 definitions, was
recorded as well as whether maternal magnesium sul-
fate was administered for seizure prevention.
Data from the inpatient postpartum course were
also abstracted from the electronic medical record,
including all systolic and diastolic BP values, all
patient-reported pain scores (on a 10-point Likert scale),
receipt of any NSAID pain medication (including
medication received and number of doses), cumulative
dose of postpartum opioid pain medication received (in
morphine milligram equivalents), and receipt of anti-
hypertensive agents postpartum. Patient-controlled
administration doses of intravenous opioid medications
were excluded from this calculation, because these data
were recorded in a separate anesthesia electronic
medical record that was not accessible to the inves-
tigators. Other variables with a potential effect on
postpartum pain control (including delivery anesthesia,
receipt of methadone maintenance therapy, and use of
any adjunctive pain medications) were recorded as well.
All postpartum patients delivered at our institution
receive the same medication orders set for postpartum
analgesia. Epidural catheters are removed in the
delivery room after vaginal delivery and in the operat-
ing room after cesarean delivery. Intrathecal morphine
is not used at our institution. Postcesarean patients are
initially managed with an intravenous opioid patient-
controlled analgesia on the day of delivery and on
postoperative day 1 are transitioned to oral medications.
Oral analgesics ordered postpartum and postoperatively
include ibuprofen as well as oxycodone–acetaminophen
Box 1. International Classification of Diseases,
9th Revision Codes for Hypertensive Disorders of
Pregnancy
Chronic hypertension (642.0, 642.1, 642.2, 642.9)
Gestational hypertension (642.3)
Preeclampsia (642.4)
Severe preeclampsia (642.5)
Superimposed preeclampsia (642.7)
Eclampsia (642.6)
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(Percocet), both administered as needed. The patient
and her nurse use shared decision-making to determine
individual dosing and frequency. In general, this process
involves an NSAID taken for mild to moderate pain and
addition of opioid medication at the lowest effective
dose for the shortest amount of time for severe pain.
Data on adverse postpartum outcomes potentially asso-
ciated with worsening hypertension as well as with
NSAID administration were also abstracted from the
electronic medical record, including incidence of post-
partum acute renal insufficiency (defined as rising post-
partum creatinine or new renal diagnosis established by
a nephrologist postpartum), need for postpartum trans-
fusion, and readmission within 30 days for a hyperten-
sive disorder.
Patients were analyzed in two cohorts according
to whether or not they received postpartum NSAIDs.
Fifteen hundred patient charts met study inclusion
criteria. The majority of patients identified received
postpartum NSAIDs. One hundred forty-seven
NSAID-unexposed patients and 1,353 NSAID-
exposed patients were identified. A subset of
NSAID-exposed patients was identified by matching
these patients one to one to NSAID-unexposed
patients chronologically on the basis of the date of
admission. Patients with missing or incomplete BP
data were then excluded, resulting in a final study
population of 129 NSAID-unexposed and 147
NSAID-exposed patients for analysis.
The primary outcome was the change in mean
arterial pressure (MAP) in mm Hg, defined as the
mean MAP from postpartum day 1 until the day of
discharge minus the mean MAP on the day of
delivery (postpartum day zero). Mean arterial pres-
sure was chosen as a primary outcome because it is
affected by both systolic and diastolic BP, which are
equally clinically significant for obstetric patients with
hypertensive disorders. Using data fromWasden et al,
we performed an a priori power calculation and
determined that 126 patients would be needed in
each group to detect a difference between the groups
in DMAP as small as 3 mm Hg (assuming a50.05,
b50.15, and SD 7.9 mm Hg).2 A Mann-Whitney test
was performed for continuous variables, and Fisher
exact test was performed for categorical variables
using Graphpad software.
Post hoc subgroup analyses by mode of delivery
and in women with and without chronic hypertension
were performed.
RESULTS
Two hundred seventy-six women with a hyperten-
sive disorder of pregnancy comprised our study
population (Table 1). The study cohorts were sim-
ilar with respect to their demographic and medical
characteristics, except that patients who did not
receive NSAIDs were more likely to have preexist-
ing renal disease (12% vs 2%, P,.01) than those
who received NSAIDs. Women who received
NSAIDs were more likely to be on antihyperten-
sive medication antepartum (most commonly labe-
talol) than those not receiving NSAIDs (35% vs
22%, P5.01).
There was no statistically significant difference in
the primary outcome, DMAP, between patients who
did and did not receive NSAIDs (20.7 vs 21.8; mean
difference 1.10, 95% CI 21.44 to 3.64; Table 2). Both
cohorts experienced a decline in BP between the day
of delivery and the remainder of their inpatient post-
partum course as evidenced by the negative values of
DMAP for both cohorts. Similarly, there were no dif-
ferences in change in systolic or diastolic pressure or
maximum systolic or diastolic BP between the groups
(Table 2).
There was no difference in rate of initiation or
dose escalation of antihypertensive agents or other
adverse postpartum events between the cohorts.
Adverse postpartum outcomes including acute renal
insufficiency, need for blood transfusion, and hospital
readmission for a hypertensive disorder did not differ
between the groups. This study was not adequately
powered to detect changes in these secondary out-
comes, however.
Similar pain scores were reported between both
study groups postpartum (Table 3). Cumulative opi-
oid use postpartum for women not receiving NSAIDs
compared with those receiving NSAIDs was 465 com-
pared with 341 morphine milliequivalents, respec-
tively, which is not statistically different (mean
difference 124.00, 95% CI 2559.90 to 807.90).
Forty-five percent of patients received additional
adjunctive pain medications postpartum in addition
to ibuprofen, oxycodone, or hydromorphone that
are standard orders. The most common additional
analgesic received was acetaminophen. There was
no difference between groups in receipt of additional
analgesic options overall or by individual agent
received (Table 3). Other factors that could affect
the need for postpartum analgesic agents, including
delivery analgesia and use of methadone maintenance
therapy, did not differ between cohorts. No difference
in any of the BP or opioid use outcomes was noted
when patients were stratified by route of delivery or
presence or chronic hypertension (Appendices 1 and
2, available online at http://links.lww.com/AOG/
B191).
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DISCUSSION
Our data suggest that administration of NSAIDs
postpartum to women with hypertensive disorders of
pregnancy is not associated with worsening hyperten-
sion and may be associated with less consumption of
opioid pain medications during the inpatient post-
partum course. These findings are in agreement with
a growing body of obstetric literature suggesting that
postpartum NSAID administration is not associated
with adverse effects on BP for women with hyperten-
sive disorders of pregnancy. In nonpregnant individ-
uals, the adverse effect of long-term use of NSAIDs on
hypertension is well known.5 This effect is particularly
pronounced in patients on antihypertensive therapy.
Table 1. Maternal Demographics
No NSAIDs (n5129) NSAIDs (n5147) P
Maternal age (y) 29.466.0 30.166.7 .38
Gestational age at delivery (wk) 35.964.4 37.163.0 .07
Cesarean delivery 43 (33) 62 (42) .06
Multiparity 53 (41) 51 (35) .31
BMI 30 kg/m2 or greater 50/110 (46) 69/124 (56) .15
Ethnicity
White 27 (21) 23 (16) .20
African American 85 (66) 102 (69) .60
Asian 10 (8) 8 (5) .40
Hispanic 1 (1) 2 (1) 1.0
Other 6 (5) 12 (8) .30
Preexisting renal disease 16 (12) 3 (2) ,.01
Pregestational diabetes 14 (11) 9 (6) .19
Gestational diabetes 15 (12) 16 (11) .85
Autoimmune disease 5 (4) 2 (1) .25
Smoking 17 (13) 20 (14) 1.0
Hypertensive diagnosis
Chronic HTN 64 (50) 60 (41) .11
On antihypertensive medication at admission 28 (22) 52 (35) .01
Gestational HTN 28 (22) 29 (20) .76
Preeclampsia 15 (12) 29 (20) .07
Preeclampsia with severe features 22 (17) 27 (19) .80
Chronic HTN with superimposed preeclampsia 4 (3) 5 (3) 1.0
Chronic HTN with superimposed preeclampsia with severe features 28 (17) 19 (13) .056
Eclampsia 0 (0) 1 (0.5) 1.0
Received magnesium sulfate 46 (36) 43 (30) .3
NSAIDs, nonsteroidal antiinflammatory drugs; BMI, body mass index; HTN, hypertension.
Data are mean6SD, n (%), or n/N (%) unless otherwise specified.
Bold indicates statistically significance.
Table 2. Postpartum Outcome Data
No NSAIDs (n5129) NSAIDs (n5147) P
DMAP (mm Hg) 20.7610.7 21.8 610.8 .31
MAP postpartum day 1 (mm Hg) 94.1 610.6 93.2621.5 .68
MAP postpartum day 2 to discharge 93.6616.4 92.2 616.8 .53
DSystolic BP (mm Hg) 20.2628.4 1.4633.7 .62
DDiastolic BP (mm Hg) 20.4617.8 1.4619.1 .43
Maximum postpartum systolic BP (mm Hg) 148.6623.4 147.1624.4 .65
Maximum postpartum diastolic BP (mm Hg) 92.4616.4 90.6616.2 .34
Postpartum initiation or dose increase of antihypertensive agent 42 (33) 44 (30) .69
Postpartum readmission for hypertensive disorder 2 (2) 1 (0.6) .66
Acute renal insufficiency 7 (5) 4 (3) .35
Postpartum transfusion 5 (4) 4 (3) .73
NSAIDs, nonsteroidal antiinflammatory drugs; MAP, mean arterial pressure; BP, blood pressure.
Data are mean6SD or n (%) unless otherwise specified.
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However, short-term use of NSAIDs is not associated
with the same effect on BP. Furthermore, the individ-
ual NSAIDs seem to differentially affect BP with nap-
roxen and indomethacin being associated with the
largest increases in BP.4
In 2004, a case series published by Makris et al
suggested NSAIDs may be dangerous in pregnant
women with hypertensive disorders. Six patients were
presented who developed hypertensive urgency after
receipt of NSAIDs (four of six received indometha-
cin).6 However, contemporary studies with control
groups have not found an association between
NSAIDs and hypertensive urgency. A retrospective
cohort study (223 women) by Wasden et al7 found
no difference in postpartum MAP or adverse postpar-
tum events in women with severe preeclampsia who
received NSAIDs compared with controls who did
not. Another retrospective cohort study by Viteri
et al (324 women) yielded similar findings: no signif-
icant difference in severe hypertension or adverse
postpartum outcomes among women with severe pre-
eclampsia who received NSAIDs compared with
those who did not. No difference was observed
between cohorts in use of opioid pain medication.8
Vigil-De Gracia et al conducted a randomized con-
trolled trial among women with superimposed pre-
eclampsia or preeclampsia with severe features.
Patients were randomized to receive ibuprofen or
acetaminophen for postpartum analgesia. Although
more postpartum hypertension was noted among
women randomized to ibuprofen, there was no differ-
ence in severe hypertension between the groups.9
Most recently, Blue et al reported no difference both
immediately postpartum and at 6 weeks postpartum
in multiple BP parameters in women with severe pre-
eclampsia randomized to ibuprofen compared with
acetaminophen. They found no difference in opioid
use between the groups.10
Our study has a number of limitations, including
its retrospective study design and a sample size
inadequate to detect differences in infrequent post-
partum adverse outcomes. Our study was also limited
by the short-term follow-up of study participants (until
hospital discharge).
Strengths of the study include being adequately
powered for our primary outcome to detect a differ-
ence as small as 3 mm Hg between the groups, which
would represent a clinically significant difference in
BP (to change MAP by 3 mm Hg, systolic BP would
need to change by 9 mm Hg or diastolic BP by 4 mm
Hg). The inclusion of an ethnically diverse population
as well as a broad spectrum of all hypertensive
disorders of pregnancy make our study results rea-
sonably generalizable.
In summary, NSAID administration to postpar-
tum patients with hypertensive disorders of preg-
nancy is not associated with an increase in BP or
increased requirement for antihypertensive medica-
tion. These findings lead us to question the recom-
mendation against use of NSAIDs postpartum in
women with hypertensive disorders of pregnancy.
Larger studies, or meta-analysis of existing studies,
may shed further light on rare adverse outcomes,
which individual studies to date have been under-
powered to evaluate.
Table 3. Postpartum Pain Scores and Analgesic Medications Administered
No NSAIDs (n5129) NSAIDs (n5147) P
Cumulative opioid dose (morphine milliequivalents) 46563,797 34161,212 .72
Mean pain score (1–10) points reported 2.261.7 2.561.6 .07
Methadone maintenance 2 (2) 6 (4) .32
Delivery anesthesia
Regional 99 (77) 125 (85) .09
General 6 (5) 2 (1) .15
Adjunctive pain medications received* 55 (43) 69 (47) .54
Gabapentin 2 (1.5) 1 (0.5) .60
Nalbuphine 6 (4.5) 15 (10) .10
Fioricet 10 (8) 9 (5) .60
Acetaminophen 28 (22) 34 (23) .90
Tramadol 6 (4.5) 1 (0.5) .05
Meperedine 2 (1.5) 3 (4.5) 1.0
Lidocaine 0 (0) 1 (1.5) 1.0
NSAIDs, nonsteroidal antiinflammatory drugs.
Data are mean6SD or n (%) unless otherwise specified.
* All opioid medications were factored into total morphine milliequivalents calculation.
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